Walgreens Boots Alliance, Inc.
WBA Details
Walgreens Boots Alliance, Inc. (NASDAQ: WBA) is a large retail drugstore chain with over 13,000 locations in 50 states and nine countries. Its fundamental approach consists of brick-and-mortar retail pharmacy outlets in high-traffic areas that serve nearly 80% of the US population. Currently, the company has a 20% of the domestic prescription medicine market.
Why should Investors Sell?
- Higher Leverage: In Q1FY22, the company's total long-term debt was USD 12.16 billion, up 1.50% from USD 11.98 billion in Q1FY21 and 40.62% from USD 8.65 billion in Q4FY21.
- Competition from Generic Drugs: The prescription rate of generic pharmaceuticals and the rate at which new generic drugs are released have an impact on segment sales, gross margin, and gross profit. Because a variety of events outside of the company's control can influence the timeframe of an overall change. The company has significant uncertainty in projecting when such adjustments will occur and how they will affect specific times in the future.
- Weak Current Ratio: In Q1FY22, the company's current ratio is 0.83x, compared to the industry median of 1.33x, indicating that liabilities are increasing.
- Trading near 52 Weeks High: The company’s stock is trading close to the 52-week high. Thus, it may face retracement from the overstretched levels.
Valuation Methodology: EV/EBITDA Multiple Based Relative Valuation
(Analysis by Kalkine Group)
WBA Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
WBA’s stock price has surged 14.39% in the past six months and is currently leaning towards the higher end of its 52-week range of USD 43.62 to USD 57.05. The stock is currently trading above its 50 and 200 DMA levels, and its RSI Index is 58.02. We have valued the stock using the EV/EBITDA multiple-based relative valuation methodology and arrived at a target price of USD 43.43.
Considering the company's growth prospects, competition in pharmacy, current valuation, and technical indicators, we believe the decent business fundamentals are adequately reflected at current trading levels. Hence, we recommend a "SELL" rating on the stock at the closing price of USD 53.18, down 0.65% as of January 20, 2022.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.